Aykon Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 09-12-2024
- Paid Up Capital ₹ 1.50 Cr
as on 09-12-2024
- Company Age 3 Year, 26 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.75 Cr
as on 09-12-2024
- Revenue %
(FY 2024)
- Profit -615354.09%
(FY 2024)
- Net Worth 7698.09%
(FY 2024)
- Total Assets 2807.16%
(FY 2024)
About Aykon Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹4.75 Cr.
Urvish Patel, Hiteshkumar Patel, Nisarg Panchal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290GJ2021PTC128132
- Company No.
128132
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aykon Biosciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Urvish Patel  | Director | 12-Mar-2024 | Current |
| Nisarg Panchal | Director | 21-Dec-2021 | Current |
| Hiteshkumar Patel | Director | 12-Mar-2024 | Current |
| Rajendra Panchal | Director | 21-Dec-2021 | Current |
| Komal Panchal | Director | 12-Mar-2024 | Current |
Financial Performance of Aykon Biosciences.
Aykon Biosciences Private Limited, for the financial year ended 2024, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 615354.09% decrease in profit. The company's net worth Soared by an impressive increase of 7698.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aykon Biosciences?
Unlock access to Aykon Biosciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aquanza Pharmaceuticals Private LimitedActive 3 years 4 monthsUrvish Patel and Hiteshkumar Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 18 Aug 2023 | ₹4.75 Cr | Open |
How Many Employees Work at Aykon Biosciences?
Aykon Biosciences has a workforce of 0 employees as of Dec 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aykon Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aykon Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
